Kardiovaskulární riziko nesteroidních antirevmatik

Nesteroidní protizánětlivé léky (non-steroidal anti-inflammatory drugs – NSAIDs) patří k nejčastěji používaným léčivům. Výsledky rozsáhlých metaanalýz klinických studií publikovaných v posledních letech ukázaly, že kardiovaskulární riziko nesteroidních antirevmatik je závažnější, než se doposud myslelo a není vázáno výlučně na koxiby. Zvyšují ho ale i tzv. tradiční nesteroidní antirevmatika. Z dosavadních poznatků vyplývá, že z pohledu kardiovaskulárního rizika k nejbezpečnějším přípravkům patří naproxen a ibuprofen v malých dávkách. Pozice naproxenu jako nejbezpečnějšího nesteroidního antirevmatika je některými novějšími nálezy poněkud zpochybňována. Autoři přispívají do diskuse o některých výsledcích metaanalýz klinických studií i závěrech regulátorů.

Klíčová slova:
diklofenak – ibuprofen – kardiovaskulární riziko – koxiby –naproxen – nesteroidní antirevmatika

Autoři: Štefan Alušík ¹; Zoltán Paluch ²
Působiště autorů: Department of Internal Medicine, Institute for Postgraduate Medical Education, Prague ¹; Department of Pharmacology, Charles University Medical School 2, Prague ²
Vyšlo v časopise: Vnitř Lék 2018; 64(3): 266-271
Kategorie: Přehledné referáty

Souhrn

Klíčová slova:
diklofenak – ibuprofen – kardiovaskulární riziko – koxiby –naproxen – nesteroidní antirevmatika

Zdroje

1. Toone EC Jr, Irby WR. Evaluation of phenylbutazone (Butazolidin) in the treatment of rheumatoid spondylitis: Report of 50 cases. Ann Intern Med 1954; 41(1): 70–78.

2. Kuzell WC, Schaffarzick RW, Brown B et al. Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. J Am Med Assoc 1952; 149(8): 729–734.

3. Hakkarainen TW, Steele SR, Bastaworous A et al. Nonsteroidal anti-inflammatory drugs and the risk for anastomotic failure: a report from Washington State’s Surgical Care and Outcomes Assessment Program (SCOAP). JAMA Surg 2015; 150(3): 223–228. Dostupné z DOI: <http://dx.doi.org/10.1001/jamasurg.2014.2239>. Erratum in Incorrect table title. [JAMA Surg. 2015].

4. Sherif BQ, Al-Zohyri AM, Shibab SS. Effects of Some Non Steroidal Anti-inflammatory Drugs on Ovulation in Women with Mild Musculoskeletal Pain (A Clinical Study). IOSR-JPBS 2014; 9(4): 43–49. Dostupné z WWW: <http://iosrjournals.org/iosr-jpbs/papers/Vol9-issue4/Version-4/G09444349.pdf>.

5. European Medicines Agency: New safety advice for diclofenac. Dostupné z WWW: <http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diclofenac-containing_medicinal_products/European_Commission_final_decision/WC500155819.pdf>.

6. [U.S. Food and Drug Administration]. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Dostupné z WWW: <https://www.fda.gov/Drugs/DrugSafety/ucm451800.htm>.

7. Bhala N, Emberson J, Merhi A et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382(9894): 769–779. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(13)60900–9>.

8. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.c7086>.

9. Schjerning Olsen AM, Fosbol E, Lindhardsen J et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123(20): 2226–2235. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.004671>.

10. Schjerning Olsen AM, Gislason GH, McGettigan P et al. Association of NSAID Use With Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction. JAMA 2015; 313(8): 805–814. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2015.0809>.

11. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 2011; 8(9): e1001098. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pmed.1001098>.

12. Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013; 22(6): 559–570. Dostupné z DOI: <http://dx.doi.org/10.1002/pds.3437>.

13. Scott PA, Kingsley GH, Scott DL. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 2008; 10(11): 1102–1107. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejheart.2008.07.013>.

14. Liu G, Yan YP, Zheng XX et al. Meta-analysis of nonsteroidal anti-inflammatory drug use and risk of atrial fibrillation. Am J Cardiol 2014; 114(10): 1523–1529. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2014.08.015>.

15. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332(7553): 1302–1308. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.332.7553.1302>.

16. MacDonald T, Hawkey C, Ford I et al. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur Heart J 2017; 38(23): 1843–1850. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehw387>. Erratum in Corrigendum [Eur Heart J 2016].

17. Grigoriou A, Ibrahim F, Chaabo K et al. Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data. Rheumatology 2016; 55(4): 763–764. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/kev386>.

18. Gnjidic D, Blyth FM, Le Couteur DG et al. Nonsteroidal anti-inflammatory drugs (NSAIDs) in older people: Prescribing patterns according to pain prevalence and adherence to clinical guidelines. Pain 2014; 155(9): 1814–1820. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pain.2014.06.009>.

19. da Costa, BR, Reichenbach, S, Keller, N et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016;387(10033):2093–2105. Retraction in: Lancet 2017; 390(10090): 109. Corrected and republished in: Lancet 2017; 390(10090): e21-e33. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(17)31744–0>.

20. Moore RA, Moore N. Paracetamol and pain: the kiloton problem. Eur J Hosp Pharm 2016; 23: 187–188. Dostupné z DOI: <http://dx.doi.org/10.1136/ejhpharm-2016–000952>.

21. Voloshyna I, Kasselman LJ, Carsons SE et al. COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages. J Investig Med 2017; 65(3): 694–704. Dostupné z DOI: <http://dx.doi.org/10.1136/jim-2016–000259>.

22. Stitham J, Hwa J. Prostacyclin, atherothrombosis and diabetes mellitus: Physiologic and clinical considerations. Curr Mol Med 2016; 16(4): 328–342.

23. Ahmetaj-Shala B, Kirkby NS, Knowles R et al. Evidence that links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine novel explanation of cardiovascular side effects associated with anti-inflammatory drugs. Circulation 2015; 131(7): 633–642. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.114.011591>.

24. Kirkby NS, Lundberg MH, Wright WR et al. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: Identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One 2014; 9(6): e98165. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0098165>.

25. Ghosh R, Hwang SM, Cui Z et al. Different effects of the nonsteroidal anti-inflammatory drugs meclofenamate sodium and naproxen sodium on proteasome activity in cardiac cells. J Mol Cell Cardiol 2016; 94: 131–34. Dostupné z DOI: <http://dx.doi.org/10.1016/j.yjmcc.2016.03.016>.

26. Garcia Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52(20): 1628–1636. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.08.041>.

27. Nissen SE, Yeomans ND, Solomon DH et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016; 375(26): 2519–2529. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611593>.

28. Bello A, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: Clinical implications. Drug Saf 2014; 37(11): 897–902. Dostupné z DOI: <http://dx.doi.org/10.1007/s40264–014–0207–2>.

29. FitzGerald GA. Imprecision: Limitations to interpretation of a large randomized clinical trial. Circulation 2017; 135(2): 113–115. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026324>.

30. Gunter BR, Butler KA, Wallace RL et al. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse event: a meta-analysis. J Clin Pharm Ther 2017; 42(1): 27–38. Dostupné z DOI: <http://dx.doi.org/10.1111/jcpt.12484>.

31. Wen IC, Hsiao FY, Chan KA et al. Acute respiratory infection and use of non-steroidal anti-inflammatory drugs on risk of acute myocardial infarction: A nation-wide case-crossover study. J Infect Dis 2017; 215(4): 503–509. Dostupné z DOI: <http://dx.doi.org/10.1093/infdis/jiw603>.

32. Zingler G, Hermann B, Fischer T et al. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risk. Expert Rev Clin Pharmacol 2016; 9(11): 1479–1492. Dostupné z DOI: <http://dx.doi.org/10.1080/17512433.2016.1230495>.

33. Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017; 357: j1909. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.j1909>.

34. Quan M. Hot Topics in Primary Care: The Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs: Putting the Evidence in Perspective. J Fam Practice 2017; 66(4 Suppl): S52-S57.

35. Ruoff G Hot topics in Primary Care: Nonsteroidal anti-inflammatory drugs and cardiovascular risk: Where are we today? J Fam Pract 2015; 64(12 Suppl): S67-S70.

36. [No authors listed]. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac. Prescrire Int 2016; 25(167): 14–16.

37. Thomas D, Ali Z, Zachariah S et al. Coxibs refocus attention on the cardiovascular risk of non-aspirin NSAIDs. Am J Cardiovasc Drugs 2017; 17(5): 343–346. Dostupné z DOI: <http://dx.doi.org/10.1007/s40256–017–0223–6>.